Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 3/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13269112 | 0.98 | LAP3 (0.37) | LAP3METAP1GABBR2GABBR1MEN1 | |
| Oxalic Acid SCHEMBL1377851 | 0.92 | LAP3 (0.33) | LAP3METAP1GABBR2GABBR1MMP1 | |
| SCHEMBL787731 | 0.83 | ALDH1A1 (0.39) | LAP3METAP1GABBR2GABBR1MEN1 | |
| SCHEMBL776263 | 0.82 | LAP3 (0.36) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL864318 | 0.80 | CYP1A2 (0.47) | GABBR2GABBR1MEN1CYP1A2KMT2A | |
| SCHEMBL371423 | 0.80 | GABBR2 (0.42) | LAP3GABBR2GABBR1MEN1CYP1A2 | |
| SCHEMBL1251447 | 0.80 | PPARD (0.35) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL11745106 | 0.80 | LAP3 (0.34) | LAP3METAP1MMP1MMP2MMP3 | |
| SCHEMBL11662649 | 0.79 | — | — | |
| SCHEMBL9203703 | 0.79 | CYP1A2 (0.42) | GABBR2GABBR1MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1155023-B1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO SPA (IT) | 2005-03-02 | — | — | EP | claimed |
| JP-2003518131-A | — | — | 2003-06-03 | — | — | JP | claimed |
| CN-1105117-C | Pharmaceutical aminophosphonic acid derivatives | SYMPHAR SA (CH) | 2003-04-09 | — | — | CN | claimed |
| US-6509324-B1 | Use as contrast agents in magnetic resonance imaging | BRACCO S.P.A. (IT) | 2003-01-21 | — | — | US | claimed |
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2003-01-16 | — | — | US | claimed |
| EP-1155023-A1 | CHELATING COMPOUNDS AND THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.p.A. (IT) | 2001-11-21 | — | — | EP | claimed |
| WO-2001046207-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | BRACCO S.P.A. (IT) | 2001-06-28 | — | — | WO | claimed |
| CN-1240451-A | Pharmaceutical aminophosphonic acid derivatives | SYMPHAR SA (CH) | 2000-01-05 | — | — | CN | claimed |
| WO-2025026797-A1 | GLYCOLYSIS OF POLYISOCYANURATE FOAMS | BASF SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| CN-105658692-A | Improved rigid polyurethane and rigid polyisocyanurate foams based on fatty acid-modified polyether polyols | 巴斯夫欧洲公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-105579484-A | Polyurethane foam premixes containing halogenated olefin blowing agents and foams made from same | HONEYWELL INT INC | 2016-05-11 | — | — | CN | disclosed |
| CN-105392859-A | Compositions and methods comprising vinylidene fluoride | HONEYWELL INT INC | 2016-03-09 | — | — | CN | disclosed |
| CN-105283507-A | Flame-retardant polycarbonate compounds which are completely non-halogenated | POLYONE CORP | 2016-01-27 | — | — | CN | disclosed |
| CN-102892849-B | curable powder coating composition and cured product thereof | NIPPON SODA CO.,LTD. (JP) | 2016-01-20 | — | — | CN | disclosed |
| WO-1996040760-A2 | IODINE-CONTAINING PEPTIDES AND THEIR USE AS X-RAY CONTRAST MEDIA | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-12-19 | — | — | WO | disclosed |
| CN-1120061-A | Binder for magnetic media | MINNESOTA MINING & MFG (US) | 1996-04-10 | — | — | CN | disclosed |
| EP-0496561-B1 | [[(2-Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives | AMERICAN HOME PROD (US) | 1995-03-15 | — | — | EP | disclosed |
| US-5240946-A | Anticonvulsants, nervous system disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
| US-5168103-A | Neuroprotectants, anticonvulsants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-12-01 | — | — | US | disclosed |
| EP-0496561-A2 | [[(2-Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013859-A1 | CHELATING COMPOUNDS, THEIR COMPLEXES WITH PARAMAGNETIC METALS | MPI, SLC39A14, LRPPRC | LAP3 1708/4885METAP1 1349/4885GABBR2 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.